223 related articles for article (PubMed ID: 20031278)
1. Cognitive effects of cell-derived and synthetically derived Aβ oligomers.
Reed MN; Hofmeister JJ; Jungbauer L; Welzel AT; Yu C; Sherman MA; Lesné S; LaDu MJ; Walsh DM; Ashe KH; Cleary JP
Neurobiol Aging; 2011 Oct; 32(10):1784-94. PubMed ID: 20031278
[TBL] [Abstract][Full Text] [Related]
2. MRZ-99030 - A novel modulator of Aβ aggregation: II - Reversal of Aβ oligomer-induced deficits in long-term potentiation (LTP) and cognitive performance in rats and mice.
Rammes G; Gravius A; Ruitenberg M; Wegener N; Chambon C; Sroka-Saidi K; Jeggo R; Staniaszek L; Spanswick D; O'Hare E; Palmer P; Kim EM; Bywalez W; Egger V; Parsons CG
Neuropharmacology; 2015 May; 92():170-82. PubMed ID: 25637092
[TBL] [Abstract][Full Text] [Related]
3. High order W02-reactive stable oligomers of amyloid-β are produced in vivo and in vitro via dialysis and filtration of synthetic amyloid-β monomer.
Robb E; Perez K; Hung LW; Masters CL; Barnham KJ; Cherny RA; Bush AI; Adlard PA; Finkelstein DI
J Alzheimers Dis; 2015; 44(1):69-78. PubMed ID: 25182735
[TBL] [Abstract][Full Text] [Related]
4. Oligomers of the amyloid-beta protein disrupt working memory: confirmation with two behavioral procedures.
Poling A; Morgan-Paisley K; Panos JJ; Kim EM; O'Hare E; Cleary JP; Lesné S; Ashe KH; Porritt M; Baker LE
Behav Brain Res; 2008 Nov; 193(2):230-4. PubMed ID: 18585407
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.
Izzo NJ; Staniszewski A; To L; Fa M; Teich AF; Saeed F; Wostein H; Walko T; Vaswani A; Wardius M; Syed Z; Ravenscroft J; Mozzoni K; Silky C; Rehak C; Yurko R; Finn P; Look G; Rishton G; Safferstein H; Miller M; Johanson C; Stopa E; Windisch M; Hutter-Paier B; Shamloo M; Arancio O; LeVine H; Catalano SM
PLoS One; 2014; 9(11):e111898. PubMed ID: 25390368
[TBL] [Abstract][Full Text] [Related]
6. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein.
Balducci C; Beeg M; Stravalaci M; Bastone A; Sclip A; Biasini E; Tapella L; Colombo L; Manzoni C; Borsello T; Chiesa R; Gobbi M; Salmona M; Forloni G
Proc Natl Acad Sci U S A; 2010 Feb; 107(5):2295-300. PubMed ID: 20133875
[TBL] [Abstract][Full Text] [Related]
7. Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers.
Gandy S; Simon AJ; Steele JW; Lublin AL; Lah JJ; Walker LC; Levey AI; Krafft GA; Levy E; Checler F; Glabe C; Bilker WB; Abel T; Schmeidler J; Ehrlich ME
Ann Neurol; 2010 Aug; 68(2):220-30. PubMed ID: 20641005
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity.
Izzo NJ; Xu J; Zeng C; Kirk MJ; Mozzoni K; Silky C; Rehak C; Yurko R; Look G; Rishton G; Safferstein H; Cruchaga C; Goate A; Cahill MA; Arancio O; Mach RH; Craven R; Head E; LeVine H; Spires-Jones TL; Catalano SM
PLoS One; 2014; 9(11):e111899. PubMed ID: 25390692
[TBL] [Abstract][Full Text] [Related]
9. Low-n oligomers as therapeutic targets of Alzheimer's disease.
Ono K; Yamada M
J Neurochem; 2011 Apr; 117(1):19-28. PubMed ID: 21244429
[TBL] [Abstract][Full Text] [Related]
10. MER5101, a novel Aβ1-15:DT conjugate vaccine, generates a robust anti-Aβ antibody response and attenuates Aβ pathology and cognitive deficits in APPswe/PS1ΔE9 transgenic mice.
Liu B; Frost JL; Sun J; Fu H; Grimes S; Blackburn P; Lemere CA
J Neurosci; 2013 Apr; 33(16):7027-37. PubMed ID: 23595760
[TBL] [Abstract][Full Text] [Related]
11. A novel drug candidate for Alzheimer's disease treatment: gx-50 derived from Zanthoxylum bungeanum.
Tang M; Wang Z; Zhou Y; Xu W; Li S; Wang L; Wei D; Qiao Z
J Alzheimers Dis; 2013; 34(1):203-13. PubMed ID: 23186988
[TBL] [Abstract][Full Text] [Related]
12. Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice.
Meilandt WJ; Cisse M; Ho K; Wu T; Esposito LA; Scearce-Levie K; Cheng IH; Yu GQ; Mucke L
J Neurosci; 2009 Feb; 29(7):1977-86. PubMed ID: 19228952
[TBL] [Abstract][Full Text] [Related]
13. Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits.
Kim HY; Lee DK; Chung BR; Kim HV; Kim Y
J Vis Exp; 2016 Mar; (109):. PubMed ID: 27023127
[TBL] [Abstract][Full Text] [Related]
14. Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport.
Sherman MA; LaCroix M; Amar F; Larson ME; Forster C; Aguzzi A; Bennett DA; Ramsden M; Lesné SE
J Neurosci; 2016 Sep; 36(37):9647-58. PubMed ID: 27629715
[TBL] [Abstract][Full Text] [Related]
15. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β.
Nussbaum JM; Schilling S; Cynis H; Silva A; Swanson E; Wangsanut T; Tayler K; Wiltgen B; Hatami A; Rönicke R; Reymann K; Hutter-Paier B; Alexandru A; Jagla W; Graubner S; Glabe CG; Demuth HU; Bloom GS
Nature; 2012 May; 485(7400):651-5. PubMed ID: 22660329
[TBL] [Abstract][Full Text] [Related]
16. Memantine rescues transient cognitive impairment caused by high-molecular-weight aβ oligomers but not the persistent impairment induced by low-molecular-weight oligomers.
Figueiredo CP; Clarke JR; Ledo JH; Ribeiro FC; Costa CV; Melo HM; Mota-Sales AP; Saraiva LM; Klein WL; Sebollela A; De Felice FG; Ferreira ST
J Neurosci; 2013 Jun; 33(23):9626-34. PubMed ID: 23739959
[TBL] [Abstract][Full Text] [Related]
17. Nicotine prevents synaptic impairment induced by amyloid-β oligomers through α7-nicotinic acetylcholine receptor activation.
Inestrosa NC; Godoy JA; Vargas JY; Arrazola MS; Rios JA; Carvajal FJ; Serrano FG; Farias GG
Neuromolecular Med; 2013 Sep; 15(3):549-69. PubMed ID: 23842742
[TBL] [Abstract][Full Text] [Related]
18. Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1-42 and suppresses microglial activity in a transgenic mouse model of Alzheimer's disease.
Manczak M; Mao P; Nakamura K; Bebbington C; Park B; Reddy PH
Hum Mol Genet; 2009 Oct; 18(20):3876-93. PubMed ID: 19617638
[TBL] [Abstract][Full Text] [Related]
19. Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease.
Paris D; Ganey NJ; Laporte V; Patel NS; Beaulieu-Abdelahad D; Bachmeier C; March A; Ait-Ghezala G; Mullan MJ
J Neuroinflammation; 2010 Mar; 7():17. PubMed ID: 20211007
[TBL] [Abstract][Full Text] [Related]
20. Brain amyloid-β oligomers in ageing and Alzheimer's disease.
Lesné SE; Sherman MA; Grant M; Kuskowski M; Schneider JA; Bennett DA; Ashe KH
Brain; 2013 May; 136(Pt 5):1383-98. PubMed ID: 23576130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
